Masahiro Yamamoto
8PUBLICATIONS
15CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Feb 18, 2026
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.Xian-Yang Qin, Yali Xu, Hricha Mishra
|Apr 12, 2022
Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi
|Nov 13, 2021
Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.Masashi Okada, Shuhei Suzuki, Keita Togashi
|Nov 12, 2021
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.Masahiro Yamamoto, Tomomi Sanomachi, Shuhei Suzuki
|Sep 28, 2021
Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction.Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi
|Jan 20, 2021
Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties.Kenta Kuramoto, Masahiro Yamamoto, Shuhei Suzuki
Pageof 2
Frequent Collaborators
1 joint publications
Masashi Okada
1 joint publications
Xian-Yang Qin
1 joint publications
Yohei Shirakami
1 joint publications
Chiao-Ling Li
1 joint publications
Kazushi Numata
1 joint publications
Feifei Wei
1 joint publications
Reiko Ando
1 joint publications
Erina Furuhata
1 joint publications
Yutaka Furutani
1 joint publications
Masanori Goto
